Monica Lupi

IRCCS Humanitas Research Hospital — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

28h-index1.9kcitations139works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(21), DNA Repair Mechanisms(17), Cancer, Lipids, and Metabolism(17), Lymphoma Diagnosis and Treatment(15), Nanoparticle-Based Drug Delivery(10)

Publications139 total

Selective antitumor activity of Tumor Treating Fields (TTFields) involving molecular factors in cancer cells and tumor microenvironment
Translational Oncology·2025Open Access
The transcriptomic fingerprint of cancer response to Tumor Treating Fields (TTFields)
Cell Death Discovery·2025· 2 citedOpen Access
Distribution of pamiparib, a novel inhibitor of poly(ADP-ribose)-polymerase (PARP), in tumor tissue analyzed by multimodal imaging
Journal of Pharmaceutical Analysis·2024Open Access
EP02.02-02 Transcriptomic Response to Tumor Treating Fields (TTFields) Across Tumor Types
Journal of Thoracic Oncology·2023Open Access
Abstract 4883: Pan cancer transcriptomic response to tumor treating fields (TTFields)
Cancer Research·2023
Abstract 1425: TTFields reduce sensitivity in glioblastoma is associated with the functional expression of the chloride intracellular channel 1 and with voltage dependent sodium channel
Cancer Research·2023
Supplementary Table 2 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplememntary Table 3 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Table 1 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Material and Methods from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Figures 1-8 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Data from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Figures 1-8 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Table 1 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Material and Methods from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Table 2 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Data from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplememntary Table 3 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Data from PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer
2023Open Access
Data from PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Paolo Ubezio(22), Maurizio D’Incalci(12), Davide Moscatelli(10), Giovanna Damia(9), Raffaele Ferrari(8), Massimo Morbidelli(8), Laura Carrassa(7), Rosaria Chilà(7), Mineko Terao(7), Maddalena Fratelli(7), Mami Kurosaki(7), Adriana Zanetti(7), Enrico Garattini(7), Francesca Falcetta(7), Gabriela Paroni(6), Maurizio Gianni’(6), Claudio Colombo(6), Massimo Broggini(5), Marco Bolis(5), Paolo Bigini(5)